Increased use of second generation antipsychotic drugs in primary care: Potential relevance for hospitalizations in schizophrenia patients

European Journal of Clinical Pharmacology

Volumn 64, Issue 1, 2008, Pages 73-76

  Cáceres, Macarena C ^a   Peñas Lledó, Eva María ^a   De La Rubia, Alfredo ^b   Llerena, Adrián ^a,c  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Hospital de Merida   (Spain)

^c HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Antipsychotic; Drug utilization; Hospitalization; Pharmacoepidemiology; Primary health care; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; ZUCLOPENTHIXOL;

ADULT; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG UTILIZATION; FEMALE; HEALTH CARE SYSTEM; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; MENTAL HEALTH CARE; PHARMACY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REIMBURSEMENT; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SPAIN;

EID: 38049071118     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0386-1     Document Type: Article

References (15)

1. Santamaria B, Perez M, Montero D, Madurga M, de Abajo FJ (2002) Use of antipsychotic agents in Spain through 1985-2000. Eur Psychiatry 17(8):471-476
2. Trifiro G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G (2005) Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol 61(1):47-53
3. Aparasu RR, Bhatara V, Gupta S (2005) U.S. national trends in the use of antipsychotics during office visits, 1998-2002. Ann Clin Psychiatry 17(3):147-152
4. Andretta M, Ciuna A, Corbari L, Cipriani A, Barbui C (2005) Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc Psychiatry Psychiatr Epidemiol 40(1):72-77
5. Mirandola M, Andretta M, Corbari L, Sorio A, Nose M, Barbui C (2006) Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. Pharmacoepidemiol Drug Saf 15(6):412-420
6. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003a) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160(7):1209-1222
7. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003b) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361(9369):1581-1589
8. Hanrahan P, Luchins DJ, Fabian R, Tolley G (2006) Cost-effectiveness of atypical antipsychotic medications versus conventional medication. Expert Opin Pharmacother 7(13):1749-1758
9. WHO Collaborating Center for Drug Statistics Methodology (WCCDSM) (1997) ATC index With DDDs for plain substances. WHO CCDSM, Oslo
10. Jones G (2003) Prescribing and taking medicines. BMJ 327(7419):819
11. Perez J, Marin N, Vallano A, Castells X, Capella D (2005) Consumption and cost of antipsychotic drugs. Actas Esp Psiquiatr 33(2):110-116
12. LLerena A, Sánchez-Vega J, Kiivet RA (1993) The use of neuroleptics and antidepressants in five European countries. In: Proceedings of the WHO Drug Utilisation Research Group Conference, Oxford
13. Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M, SOHO Study Group (2006) Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 26(6):571-578
14. Gianfrancesco F, Wang RH, Pesa J, Rajagopalan K (2006) Hospitalization risks in treatment of schizophrenia Medicaid population: comparison of antipsychotic medications. Int J Clin Pract 60(11):1419-1424
15. Meltzer HY, Bobo WV (2006) Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr 11(7):14-24